AR092348A1 - DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc - Google Patents
DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORcInfo
- Publication number
- AR092348A1 AR092348A1 ARP130102439A ARP130102439A AR092348A1 AR 092348 A1 AR092348 A1 AR 092348A1 AR P130102439 A ARP130102439 A AR P130102439A AR P130102439 A ARP130102439 A AR P130102439A AR 092348 A1 AR092348 A1 AR 092348A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aminocarbonyl
- alkoxy
- several times
- substituted once
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en la que: m es el número 0 ó 1; n es el número 0 ó 1; p es un número de 0 a 3; q es el número de 0, 1 ó 2; r es un número de 1 a 3; A es: un enlace; -(CRʲRᵏ)ₜ-; -C(O)-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-C(O)-; -NRᵃ-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-NRᵃ-; -C(O)NRᵃ-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-NRᵃC(O)-; -O-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-O-; -S-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-S-; -SO₂-(CRʲRᵏ)ₜ-; o -(CRʲRᵏ)ₜ-SO₂-; t es un número de 0 a 4; W es: -CRᵇRᶜ-; -O-; -S-; -SO₂-; o -NRᵈ-; uno de X¹, X², X³ y X⁴ es N y los demás son CRᵉ; o dos de X¹, X², X³ y X⁴ son N y los demás son CRᵉ; o tres de X¹, X², X³ y X⁴ son N y el restante es CRᵉ; o cada uno de X¹, X², X³ y X⁴ es CRᵉ; Y es: -O-; -S-; SO₂-; -CRᶠRᵍ-; o -NRʰ-; Z es: CH; o N; R¹, R², R³, R⁴, R⁵, R⁶, R⁷ y R⁸ con independencia entre sí son: hidrógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno; o R³ y R⁴ junto con el átomo al que están unidos pueden formar un grupo etileno; o R³ y R⁴ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o R⁵ y R⁶ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o R⁷ y R⁸ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de R³ y R⁴ junto con uno de R⁵ y R⁶ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de R⁵ y R⁶ junto con uno de R⁷ y R⁸ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; cada R⁹ es con independencia: alquilo C₁₋₆; halógeno; alcoxi C₁₋₆; o ciano; dichos restos alquilo C₁₋₆ pueden estar sin sustituir o sustituidos una o varias veces por halógeno; R¹⁰ es: hidrógeno; carboxi; (alquil C₁₋₆)-carbonilo; (alcoxi C₁₋₆)-carbonilo; oxo; hidroxi; aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; N,N-di(alquil C₁₋₆)-aminocarbonilo; ciano; hidroxi-alquilo C₁₋₆; N-(alcoxi C₁₋₆)-(alquil C₁₋₆)-amino-carbonilo; N-hidroxi-(alquil C₁₋₆)-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; halógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno u oxo; R¹¹ es: hidrógeno; halógeno; carboxi; (alquil C₁₋₆)-carbonilo; (alcoxi C₁₋₆)-carbonilo; oxo; hidroxi; aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; N,N-di-(alquil C₁₋₆)-aminocarbonilo; (alquil C₁₋₆)-sulfonil-amino; (alquil C₁₋₆)-sulfonil-amino-alquilo C₁₋₆ ciano; hidroxi-alquilo C₁₋₆ N-(alcoxi C₁₋₆)-(alquil C₁₋₆)-aminocarbonilo; N-hidroxi-(alquil C₁₋₆)-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno u oxo; R¹² es: hidrógeno; halógeno; carboxi; (alquil C₁₋₆)-carbonilo; (alcoxi C₁₋₆)-carbonilo; oxo; hidroxi; aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; N,N-di-(alquil C₁₋₆) -aminocarbonilo; ciano; hidroxi-alquilo C₁₋₆; N-(alcoxi C₁₋₆)-(alquil C₁₋₆)-aminocarbonilo; N-hidroxi-(alquil C₁₋₆)-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno u oxo; o R¹⁰ y R¹¹ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; Rᵃ, Rᵇ, Rᶜ y Rᵈ con independencia entre sí son: hidrógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno; o Rᵇ y Rᶜ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de Rᵇ y Rᶜ junto con uno de R⁷ y R⁸ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de Rᵇ y Rᶜ junto con uno de R⁵ y R⁶ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; cada Rᵉ es con independencia: hidrógeno; alquilo C₁₋₆; halógeno; alcoxi C₁₋₆; o ciano; dichos restos alquilo C₁₋₆ pueden estar sin sustituir o sustituidos una o varias veces por halógeno; Rᶠ es: hidrógeno; halógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno; Rᵍ es: hidrógeno; alquilo C₁₋₆; cicloalquilo C₃₋₆; cicloalquenilo C₃₋₆; (cicloalquil C₃₋₆)-alquilo C₁₋₆; halógeno; (alquil C₁₋₆)-carbonilo; (cicloalquil C₃₋₆)-carbonilo; (cicloalquil C₃₋₆)-(alquil C₁₋₆)-carbonilo; ciano-(alquil C₁₋₆)-carbonilo; hidroxi-(alquil C₁₋₆)-carbonilo; alcoxi C₁₋₆-(alquil C₁₋₆)-carbonilo; carboxi; N-ciano-aminocarbonilo; N-ciano-N-(alquil C₁₋₆)-aminocarbonilo; N-(alquil C₁₋₆)-acetimidamidilo; N,N-di-(alquil C₁₋₆)-acetimidamidilo; N-ciano-N-(alquil C₁₋₆)-acetimidamidilo; N-hidroxi-acetimidamidilo; N-alcoxi C₁₋₆-acetimidamidilo; N-hidroxi-N-(alquil C₁₋₆)-acetimidamidilo; N-(alcoxi C₁₋₆)-N-(alquil C₁₋₆)-acetimidamidilo; 2-nitro-1-N-(alquil C₁₋₆)-amino-vinilo; formilo; (alquil C₁₋₆)-sulfonilo; (cicloalquil C₃₋₆)-sulfonilo; (cicloalquil C₃₋₆)-(alquil C₁₋₆)-sulfonilo; (alquil C₁₋₆)-sulfonil-alquilo C₁₋₆; aminocarbonilo; N-hidroxi-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; aminocarbonil-alquilo C₁₋₆; N-(alquil C₁₋₆)-aminocarbonil-alquilo C₁₋₆; N,N-di-(alquil C₁₋₆)-aminocarbonil-alquilo C₁₋₆; (alcoxi C₁₋₆)-carbonilo; N-hidroxi-N-(alquil C₁₋₆)-aminocarbonilo; N-alcoxi C₁₋₆-N-(alquil C₁₋₆)-aminocarbonilo; N,N-di(alquil C₁₋₆)-aminocarbonilo; aminosulfonilo; N-(alquil C₁₋₆)-aminosulfonilo; N,N-di-(alquil C₁₋₆)-aminosulfonilo; ciano; alcoxi C₁₋₆ (alquil C₁₋₆)-sulfonil-amino; N-(alquil C₁₋₆)-sulfonil-aminocarbonilo; N-(alqui
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670519P | 2012-07-11 | 2012-07-11 | |
US201361788430P | 2013-03-15 | 2013-03-15 | |
US201361837461P | 2013-06-20 | 2013-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092348A1 true AR092348A1 (es) | 2015-04-15 |
Family
ID=48782328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102439A AR092348A1 (es) | 2012-07-11 | 2013-07-10 | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc |
Country Status (21)
Country | Link |
---|---|
US (1) | US9115101B2 (es) |
EP (1) | EP2872504B1 (es) |
JP (1) | JP6262228B2 (es) |
KR (1) | KR20150029739A (es) |
CN (2) | CN107235867A (es) |
AR (1) | AR092348A1 (es) |
AU (1) | AU2013288756A1 (es) |
BR (1) | BR112015000581A2 (es) |
CA (1) | CA2876449A1 (es) |
CL (1) | CL2014003572A1 (es) |
CO (1) | CO7141456A2 (es) |
CR (1) | CR20140548A (es) |
ES (1) | ES2612165T3 (es) |
HK (2) | HK1208679A1 (es) |
IL (1) | IL236293A0 (es) |
MX (1) | MX2015000325A (es) |
PE (1) | PE20151007A1 (es) |
PH (1) | PH12014502788B1 (es) |
SG (1) | SG11201408534VA (es) |
TW (1) | TW201408652A (es) |
WO (1) | WO2014009447A1 (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8629274B2 (en) | 2011-12-21 | 2014-01-14 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
MY175061A (en) | 2012-04-26 | 2020-06-04 | Bristol Myers Squibb Co | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
JP2015533782A (ja) | 2012-08-28 | 2015-11-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 |
ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
AR094664A1 (es) | 2013-01-15 | 2015-08-19 | Incyte Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
EP2961732B1 (en) | 2013-02-28 | 2017-04-12 | Janssen Sciences Ireland UC | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
AU2014267235B2 (en) | 2013-05-17 | 2017-10-05 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN105308042A (zh) * | 2013-06-21 | 2016-02-03 | 豪夫迈·罗氏有限公司 | 作为RORc 调节剂的芳基磺内酰胺衍生物 |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN105658653A (zh) | 2013-08-23 | 2016-06-08 | 因赛特公司 | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 |
KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도 |
CA2932888A1 (en) * | 2014-01-10 | 2015-07-16 | F. Hoffmann-La Roche Ag | Aryl sultam derivatives as rorc modulators |
RU2016131363A (ru) * | 2014-01-10 | 2018-02-16 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ АРИЛСУЛЬТАМА В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРФАННОГО РЕЦЕПТОРА γ, СВЯЗАННОГО С РЕТИНОЕВОЙ КИСЛОТОЙ |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
CA2938311C (en) | 2014-02-03 | 2023-03-07 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
CN106232136A (zh) | 2014-02-05 | 2016-12-14 | 诺维拉治疗公司 | 用于治疗hbv感染的联合疗法 |
AU2015214961B2 (en) | 2014-02-06 | 2018-08-30 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
CN104370755B (zh) * | 2014-08-18 | 2017-04-12 | 江西隆莱生物制药有限公司 | 一种光学活性的3‑氨基丁醇和3‑氨基丁酸的制备方法 |
EA031967B1 (ru) | 2014-10-14 | 2019-03-29 | Вайтаи Фармасьютиклз, Инк. | ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ |
WO2016069498A1 (en) * | 2014-10-26 | 2016-05-06 | Galileo Group, Inc. | Temporal processes for aggregating multi dimensional data collection from discrete and distributed collectors using machine-to-machine networks and smartphones to provide enhanced space-time perspective for monitoring changes using algorithmic techniques |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
CN107108600A (zh) * | 2014-12-17 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 作为RORc调节剂的杂芳基亚烷基芳基磺内酰胺衍生物 |
WO2016110821A1 (en) | 2015-01-08 | 2016-07-14 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN107690431A (zh) * | 2015-07-08 | 2018-02-13 | 豪夫迈·罗氏有限公司 | 作为RORc调节剂的芳基磺内酰胺衍生物 |
WO2017005668A1 (en) * | 2015-07-08 | 2017-01-12 | F. Hoffmann-La Roche Ag | ARYL SULTAM DERIVATIVES AS RORc MODULATORS |
DK3331876T3 (da) | 2015-08-05 | 2021-01-11 | Vitae Pharmaceuticals Llc | Modulators of ror-gamma |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
KR20180086221A (ko) | 2015-11-20 | 2018-07-30 | 비타이 파마슈티컬즈, 인코포레이티드 | Ror-감마의 조절물질 |
TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
CN109640980A (zh) | 2016-04-15 | 2019-04-16 | 诺维拉治疗公司 | 包含壳体装配抑制剂的组合和方法 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
CA3042080A1 (en) * | 2016-10-27 | 2018-05-03 | Escalier Biosciences, Bv | Ror-gamma modulators |
CN106966912B (zh) * | 2017-04-01 | 2019-07-02 | 沧州那瑞化学科技有限公司 | (r)-3-氨基丁醇的制备方法 |
JP7258009B2 (ja) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
CN115650976A (zh) | 2017-07-24 | 2023-01-31 | 生命医药有限责任公司 | RORγ的抑制剂 |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
TW201910312A (zh) * | 2017-07-28 | 2019-03-16 | 日商東麗股份有限公司 | 環狀胺衍生物及其醫藥用途 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US11242350B2 (en) | 2018-03-12 | 2022-02-08 | Escalier Biosciences B.V. | Spirocyclic ROR-gamma modulators |
JP2021517563A (ja) * | 2018-03-12 | 2021-07-26 | エスカリア バイオサイエンシーズ,ビーブイ | 二環式RORγモジュレーター |
WO2019175657A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
KR20210130753A (ko) | 2019-02-22 | 2021-11-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체 |
MX2021011606A (es) | 2019-04-02 | 2021-12-10 | Aligos Therapeutics Inc | Compuestos dirigidos a prmt5. |
MX2021013594A (es) | 2019-05-06 | 2021-12-10 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. |
CN117500785A (zh) | 2021-06-16 | 2024-02-02 | 细胞基因公司 | 用于治疗神经退化性疾病的含羧酸氮杂环丁烷基化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101351209A (zh) * | 2005-11-01 | 2009-01-21 | 转化技术制药公司 | 取代的酰胺的药学应用 |
AU2006310518A1 (en) * | 2005-11-01 | 2007-05-10 | High Point Pharmaceuticals, Llc | Pharmaceutical use of substituted amides |
CN102482228A (zh) * | 2009-07-17 | 2012-05-30 | 盐野义制药株式会社 | 含有内酰胺或苯磺酰胺化合物的药物 |
EP2368886A1 (en) * | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease |
US9512111B2 (en) * | 2010-11-08 | 2016-12-06 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
PE20142400A1 (es) | 2012-04-27 | 2015-02-04 | Glaxo Group Ltd | Compuestos novedosos |
-
2013
- 2013-07-10 AR ARP130102439A patent/AR092348A1/es unknown
- 2013-07-10 TW TW102124802A patent/TW201408652A/zh unknown
- 2013-07-11 ES ES13735278.7T patent/ES2612165T3/es active Active
- 2013-07-11 SG SG11201408534VA patent/SG11201408534VA/en unknown
- 2013-07-11 JP JP2015520984A patent/JP6262228B2/ja not_active Expired - Fee Related
- 2013-07-11 AU AU2013288756A patent/AU2013288756A1/en not_active Abandoned
- 2013-07-11 CN CN201710559460.1A patent/CN107235867A/zh active Pending
- 2013-07-11 CN CN201380036729.8A patent/CN104470917B/zh not_active Expired - Fee Related
- 2013-07-11 CA CA2876449A patent/CA2876449A1/en not_active Abandoned
- 2013-07-11 MX MX2015000325A patent/MX2015000325A/es unknown
- 2013-07-11 EP EP13735278.7A patent/EP2872504B1/en not_active Not-in-force
- 2013-07-11 KR KR20157003144A patent/KR20150029739A/ko not_active Application Discontinuation
- 2013-07-11 BR BR112015000581A patent/BR112015000581A2/pt not_active IP Right Cessation
- 2013-07-11 PE PE2015000022A patent/PE20151007A1/es not_active Application Discontinuation
- 2013-07-11 WO PCT/EP2013/064637 patent/WO2014009447A1/en active Application Filing
- 2013-07-11 US US13/939,962 patent/US9115101B2/en not_active Expired - Fee Related
-
2014
- 2014-11-28 CO CO14262762A patent/CO7141456A2/es unknown
- 2014-12-01 CR CR20140548A patent/CR20140548A/es not_active Application Discontinuation
- 2014-12-15 IL IL236293A patent/IL236293A0/en unknown
- 2014-12-15 PH PH12014502788A patent/PH12014502788B1/en unknown
- 2014-12-30 CL CL2014003572A patent/CL2014003572A1/es unknown
-
2015
- 2015-09-24 HK HK15109405.3A patent/HK1208679A1/xx not_active IP Right Cessation
-
2018
- 2018-03-23 HK HK18104078.7A patent/HK1244781A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IL236293A0 (en) | 2015-02-26 |
ES2612165T3 (es) | 2017-05-12 |
AU2013288756A1 (en) | 2015-01-15 |
EP2872504B1 (en) | 2016-11-16 |
US20140031330A1 (en) | 2014-01-30 |
PH12014502788A1 (en) | 2015-02-09 |
HK1244781A1 (zh) | 2018-08-17 |
EP2872504A1 (en) | 2015-05-20 |
CL2014003572A1 (es) | 2015-04-24 |
JP2015522057A (ja) | 2015-08-03 |
SG11201408534VA (en) | 2015-02-27 |
JP6262228B2 (ja) | 2018-01-17 |
PH12014502788B1 (en) | 2015-02-09 |
CR20140548A (es) | 2015-02-12 |
TW201408652A (zh) | 2014-03-01 |
CA2876449A1 (en) | 2014-01-16 |
CN104470917A (zh) | 2015-03-25 |
MX2015000325A (es) | 2015-04-14 |
HK1208679A1 (en) | 2016-03-11 |
CN107235867A (zh) | 2017-10-10 |
CO7141456A2 (es) | 2014-12-12 |
BR112015000581A2 (pt) | 2017-06-27 |
US9115101B2 (en) | 2015-08-25 |
PE20151007A1 (es) | 2015-06-29 |
KR20150029739A (ko) | 2015-03-18 |
CN104470917B (zh) | 2017-08-04 |
WO2014009447A1 (en) | 2014-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092348A1 (es) | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc | |
AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR095464A1 (es) | Compuestos de heteroarilo y usos de los mismos | |
AR100137A1 (es) | Compuestos 4-amino-imidazoquinolina | |
AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR106763A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
DOP2010000272A (es) | Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
CR20160578A (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR095164A1 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |